Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06632262 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Phase 2 Clinical Study of ABSK061 and ABSK043

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Trial status: Not Yet Recruiting to Recruiting Start date changed from estimate of Nov 30, 2024 to Nov 13, 2024 · Site details revised at 21 of 21 sitesv2 Show 2 more changesShow less
    • Start date changed from estimate of Nov 30, 2024 to Nov 13, 2024
    • Site details revised at 21 of 21 sites
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this study is to evaluate the anti-tumor activity of ABSK061 + ABSK043 in terms of overall response rate (ORR) in in Patients with Metastatic/Unresectable Solid Tumors with FGFR2/3 Alterations
Trial Details
NCT Number NCT06632262
Lead Sponsor Abbisko Therapeutics Co, Ltd
Conditions HER2-Gastric/Gastroesophageal Junction Cancer, Urothelial Carcinoma, Non-Small Cell Lung Cancer, Solid Tumors
Enrollment 202 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov